Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cloxazolam is a long-acting benzodiazepine derivative with anxiolytic (anti-anxiety), sedative/hypnotic, muscle relaxant, and antiepileptic properties. It acts as a prodrug and is metabolized in the liver to its active metabolite delorazepam (chlordesmethyldiazepam). The primary mechanism of action involves positive allosteric modulation of the GABA(A) receptor at the benzodiazepine binding site, enhancing the inhibitory effect of GABA in the central nervous system. Cloxazolam is mainly indicated for short-term treatment of anxiety disorders but has also been used for sleep disorders (such as insomnia), premedication before surgery to reduce anxiety and tension, and as adjunctive therapy in epilepsy. It has been marketed primarily in Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cloxazolam.